EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY

https://storage.unitedwebnetwork.com/files/1099/4b222506acd0a6238150f06a032c363f.pdf
EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
Hiddo
J.L. Heerspink
David C. Wheeler d.wheeler@ucl.ac.uk University College London Department of Renal Medicine London
Ricardo Correa-Rotter correarotter@gmail.com The National Medical Science and Nutrition Institute Salvador Zubiran Department of Nephrology and Mineral Metabolism Mexico city
Jamie P. Dwyer jamie.dwyer@hsc.utah.edu University of Utah Division of Nephrology and Hypertension Salt Lake City
Anna Maria Langkilde AnnaMaria.Langkilde@astrazeneca.com AstraZeneca BioPharmaceuticals R&D Gothenburg
Patrick B. Mark Patrick.Mark@glasgow.ac.uk University of Glasgow / Queen Elizabeth University Hospital School of Cardiovascular and Metabolic Health / Renal & Transplant Unit Glasgow
Michal Nowicki michal.nowicki@umed.lodz.pl Medical University of Lodz Department of Nephrology, Hypertension and Kidney Transplantation Lodz
Peter Rossing peter.rossing@regionh.dk University of Copenhagen / Steno Diabetes Center Copenhagen Department of Clinical Medicine Gentofte / Copenhagen
Robert D. Toto Robert.Toto@UTSouthwestern.edu UT Southwestern Medical Center Department of Internal Medicine Dallas
Glenn M. Chertow gchertow@stanford.edu Stanford University Departments of Medicine and Epidemiology and Population Stanford
Niels Jongs n.jongs@umcg.nl University of Groningen Department of Clinical Pharmacy and Pharmacology Groningen
 
 
 
 
 
E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos